PLK2 was shown to be a tumor suppressor in breast cancer (basal-like and triple-negative breast cancer subtypes) and loss of PLK1 rescued phenotypes after PLK2 knockdown in vitro and in vivo. Here, PLK2 is linked to breast carcinoma.